A standard calcium score cannot provide a complete picture of cardiovascular risk, as it only detects calcified plaque and misses the soft, lipid-rich plaque most associated with acute coronary events. We utilize advanced coronary CTA enhanced by either Cleerly’s FDA-cleared AI to quantify both calcified and non-calcified plaque, assess vessel-level stenosis, and evaluate the likelihood of ischemia, or HeartFlow’s non-invasive FFRct analysis to model functional flow and identify lesions that may require intervention. This comprehensive approach provides earlier, more accurate insights—supporting proactive decision-making for asymptomatic patients before disease becomes critical.

Our state-of-the-art CT scanner uses low-dose radiation and a safe contrast agent to capture clear, detailed images of your patients body—all in just minutes. This scan is designed to detect early signs of cancer in vital organs like the lungs, liver, kidneys, and pancreas, often before symptoms begin. It’s a fast, non-invasive way to take control of their health with confidence and clarity.

Following the scan, our medical team will conduct a post-imaging consultation with the patient to review key findings and address immediate questions. Patients are then referred back to your practice for a full review of the detailed diagnostic report, allowing you to guide next steps within the context of their ongoing care. If desired, we can also establish provider access to our AI-powered reporting platform to support direct interpretation and patient communication. This creates a natural opportunity for a follow-up visit—fully billable—while maintaining continuity of care within your practice.